NSI-189 is a acts on glucocorticoid receptors, separating it from other candidates tried for depression (which are primarily serotonergic). It was tried due to findings of decreased hippocampal growth in depressed patients, which NSI-189 would in theory remedy due to its neurotrophic effects. It had success in early trials, but ultimately failed later on. Still new interest is sparked in this compound due to its potential nootropic effects.
Scientific discussion is purely for educational purposes. This is not medical advice.